FDA Approves Aducanumab for Alzheimer's Disease
June 9, 2021
The U.S. Food and Drug Administration (FDA) today approved aducanumab (Biogen/Eisai) to treat Alzheimer’s disease.
This is the first drug that slows Alzheimer’s disease. And, this is the beginning of a completely new future for Alzheimer’s treatments. This is a new type of Alzheimer’s treatment; it addresses the disease in a way that has never been done before, compared to currently approved drugs.
Alzheimer’s — a progressive, degenerative and fatal brain disease — is the most common cause of dementia. For Alzheimer’s Disease Facts and Figures, an annual report by the Alzhe...
For access to this article please sign in or subscribe.